EBD Group is part of the Knowledge and Networking Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Informa
Key Sessions

Greg B. Scott

Ten years of evolution in China: A global perspective

ChinaBio® Group

Annie Siu, PhD, MBA

Innovation in China: Immuno-therapy and beyond

Pharma Intelligence | Informa

Day 1 - 2018
Show Filter
08:00 - 18:00 600 mins
Registration
Registration
more

Hotel Lobby (2F)

08:00 - 09:00 60 mins
Networking
Continental Breakfast
09:00 - 09:20 20 mins
Panel
Welcome Remarks
  • Speaker Susanna Ling - Director, Business and Program Development, EBD Group
  • Speaker Greg B. Scott - Founder and Chairman, ChinaBio® Group
  • Speaker Yaping Li, PhD - Mayor, Suzhou Municipal Government
more
09:20 - 10:30 70 mins
Panel
Ten years of evolution in China: A global perspective
  • Moderator Greg B. Scott - Founder and Chairman, ChinaBio® Group
  • Panelist Bin Li, PhD - Director, Search & Evaluation, JAPAC, AbbVie
  • Panelist Yong Jun Liu - Global Head of Research, Senior VP R&D, Sanofi
  • Panelist Sophie Sun, MBA - VP, Head of Innovation Hub China, Head of Strategy & Transformation China, Merck
  • Panelist Ben Thorner, JD - Senior VP and Head of Global BD and Licensing, MSD
  • Panelist Dan Wang, MD, MBA - Head, Johnson & Johnson Innovation, Asia Pacific, J&J
  • Panelist Zaiqi Wang, MD PhD - Site Head, Roche Innovation Center, Shanghai, Roche
more

State Ballroom

China’s pharmaceutical industry is rapidly evolving from its domestic foundation to a global horizon. There is a shift in big pharma from bringing their existing products to China, to developing and in-licensing new candidates in China for the world. In the rush to access new innovation, pharma are establishing innovation centers and external development teams in China to capture technology and talent and apply them to the global stage. Stoking the fire, a government-led revolution is underway that is creating significant opportunities for the pharma industry: New regulatory, reimbursement and pricing policies are speeding the entry of imported drug products and catalyzing the development of new drugs in China. This panel of global leaders from big pharma will examine the changing landscape in China and how this is affecting their business, and yours, both domestically and globally.

10:30 - 18:00 450 mins
Company Presentations
Company Presentations
more

K4 (1F)

10:30 - 18:00 450 mins
Partnering: one-to-one meetings
One-to-one meetings
more

Grand Ballroom (2F) & K9 Foyer (1F)

10:30 - 11:00 30 mins
Networking
Networking Break
more

Exhibit Area (2F)

11:00 - 12:00 60 mins
Panel
Innovation in China: Immuno-therapy and beyond
  • Moderator Annie Siu, PhD, MBA - Principal Analyst, Pharma Intelligence | Informa
  • Panelist Yuan-Hua Ding, PhD - Executive Director and Head of External Science & Innovation (ES&I) – Asia/Pacific,, Pfizer Worldwide R&D
  • Panelist Ming Wang, PhD, MBA - Founder, President and CEO, Phanes Therapeutics
  • Panelist Zheng Wei, PhD - CEO and Co-Founder, Connect Biopharma
  • Panelist Pengcheng Zhu, PhD, MBA - CEO and Co-Founder, ATLATL
more

Rooms K2 & K3 (1F)

With strong government support, significant VC funding and a positive regulatory environment, China has rapidly become a leading innovator in biopharmaceuticals, and this is especially true in immuno-therapy. There are over 140 companies in China developing immuno-therapy assets, with over CAR-T 80 candidates in the clinic, putting China #2, just behind the US. China is also committed to CRISPR, having edited genes of 86 people, more than any other country. Learn more about how China is positioned to lead the immuno-therapy revolution from the founders of some of the most innovative companies in China.

12:00 - 13:30 90 mins
Networking
Luncheon
more

Grand Ballroom (2F) and K7 & K8 (1F)

13:30 - 14:30 60 mins
Panel
New horizons for innovative life sciences companies in China: Global IPO and M&A opportunities
  • Moderator Thomas Chou, JD - Partner, Morrison & Foerster
  • Panelist Irene Hong, MBA - Founding Partner, CEC Capital Group
  • Panelist Bin Li, PhD, MBA - Founder and Chief Investment Officer, Ally Bridge LB Healthcare Fund
  • Panelist Martin Shen, MBBS - CEO and Founder, XingRen Doctor
  • Panelist Yu Wang, PhD - Of Counsel, Morrison & Foerster
  • Panelist Janet Xiao, PhD, JD - Partner, Morrison & Foerster
more

Rooms K2 & K3 (1F)

With M&A deal value tripling to USD 65 billion in 2017, the life sciences sector is expected to continue its growth in M&A activities this year thanks to strong capital markets and positive regulatory changes, including the Hong Kong Exchange's imminent move to allow pre-revenue biopharma companies to list on the HKEX. In this session, a panel of practitioners and industry leaders will explore the pros and cons of a number of fund raising methods in China and globally, and discuss how to establish financial and IP strategies tailored to your company that can help ensure long-term success.  

14:30 - 15:30 60 mins
Panel
Accelerating market entry and access in China: Lessons from high value therapies
  • Moderator Helen Chen - Managing Director, Head of China Life Sciences, L.E.K. Consulting
  • Panelist Stephen Doyle - General Manager China, ASLAN Pharmaceuticals
  • Panelist Justin Wang - Managing Director, L.E.K. Consulting
more

China is upgrading its pharma industry to enhance innovation, so everyone says. What does that mean in terms of regulatory ease, shortened timelines, good pricing, reimbursement coverage and hospital access? While all the trends and most policies are pointing in the right direction, China is still a complicated market with many interpretations. Join the senior executives in the industry as we exchange viewpoints on working through the system in China and suggestions for international biopharmas considering the China market.

15:30 - 16:00 30 mins
Networking
Networking Break
more

Exhibit Area (2F)

16:00 - 17:00 60 mins
Panel
China opportunities: Optimizing deals with European target companies
  • Moderator Peter Homberg - Partner, Dentons
  • Panelist Jason Cheng - Senior Partner, Dentons Shanghai Office
  • Panelist Kevin Li - Managing Partner, LYZZ Capital
more

Rooms K2 & K3 (1F)

Europe has become progressively more attractive for Chinese investors. As a result, the number of M&A transactions involving Chinese investors and targets in Europe, and in particular in Germany, continuously increase. On the one hand, these circumstances offer attractive opportunities for companies and investors. On the other hand, it is not uncommon that transactions fail due to cultural differences and misunderstandings in the communication. There are also several legal hurdles that have to be overcome and must be taken into account in order to successfully complete such cross-border transactions. This session will be focused on experiences and typical problems of dealing with targets in Europe, and practical solutions.

18:30 - 21:00 150 mins
Networking
Gala Reception
more

Crowne Plaza Suzhou
168 Xinggang Street
Suzhou, China

21:00–21:30 Shuttle buses from Gala Reception to Kempinski Hotel